微生态制剂联合美沙拉嗪治疗轻中度溃疡性结肠炎临床疗效

Therapeutic effects of combination treatment of Mesalazine and Bifico in patients with mild or moderate ulcerative colitis

目的评价微生态制剂联合美沙拉嗪治疗轻中度溃疡性结肠炎的临床疗效。方法选取2012年1月至2014年12月来瑞安市人民医院治疗的轻中度溃疡性结肠炎患者52例,将其随机分成对照组和治疗组,对照组采用美沙拉嗪治疗,治疗组采用美沙拉嗪联合微生态制剂治疗,治疗8周后分别对两组患者的CRP、ESR、内镜评分、疾病活动指数(DAI)以及不良反应情况进行比较。结果在治疗8周后,治疗组CRP、ESR、内镜评分及DAI均低于对照组,差异有统计学意义(P<0.05);两组患者不良反应相比差异无统计学意义(P>0.05)。结论微生态制剂联合美沙拉嗪治疗轻中度溃疡性结肠炎疗效明显,且联合治疗明显优于单纯美沙拉嗪治疗,无明显不良反应,值得临床推广。

Objective To evaluate the efficiency of combination of Mesalazine and Bifico in patients with mild or moderate ulcerative colitis（UC）.Methods 52 patients with active mild or moderate ulcerative colitis were randomly divided into Trial group（n=26）or Control group（n=26）.The patients in Control group were treated with Mesalazine for 8weeks while the patients in Trial group were treated with Mesalazine and Bifico for 8weeks.After 8weeks,the CRP,ESR,endoscopic score,disease active index（DAI）and adverse reaction of patients were compared between the two groups.Results The CRP,ESR,endoscopic score and DAI were significantly lower in Trial group than in Control group（P〈0.05）.The adverse reaction wasn′t statistically significant between two groups（P〉0.05）.Conclusion The combination treatment of Mesalazine and Bifico is more effective than oral Mesalazine alone in treatment of mild or moderately active UC.